Compare Amylx Pharmaceuticals Inc (AMLX) vs First Trust NASDAQ Clean Edge Green Energy Idx Fd (QCLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs First Trust NASDAQ Clean Edge Green Energy Idx Fd — how do they compare? Amylx Pharmaceuticals Inc trades at $23.49 (market cap $2.64B), while First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $53.21. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, First Trust NASDAQ Clean Edge Green Energy Idx Fd nearer its low. Which is the better fit depends on your goals.
| AMLX | QCLN | |
|---|---|---|
Market Cap | $2.64B | — |
Sector | Health | Sector/Thematic |
52-Week High | $24.19 | $68.47 |
52-Week Low | $7.82 | $36.11 |
Enterprise Value | $2.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.
The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.
QCLN trades at $53.17, up 2.15% today, with a bullish technical signal from moving averages but neutral oscillators. Recent news highlights clean energy ETF growth driven by data center demand and geopolitical shifts, though regulatory hurdles and supply chain costs pose challenges. The stock lacks disclosed financial ratios, requiring deeper fundamental review.
Outlook is cautiously optimistic given sector tailwinds, but investment hinges on policy stability and cost management. Risks include U.S. permit delays and Chinese trade tensions, while institutional sentiment appears mixed amid volatile clean energy markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About First Trust NASDAQ Clean Edge Green Energy Idx Fd
QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →
